Dose Response to Recombinant Factor VIIa When Administered for Bleed

Novo Nordisk

Status and phase: Completed; Phase 1

Conditions: Healthy; Congenital Bleeding Disorder

Treatments: Drug: activated recombinant human factor VII

Study type: Interventional

Funder types: Industry

Identifiers

NCT00104455

F7DRC-2157

Details and patient eligibility

About

This trial is conducted in the United States of America (USA). The purpose of this trial is to investigate the dose response to recombinant factor VIIa in healthy volunteers when administered for bleed.

Enrollment: 64 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ages Eligible for Study: 18 Years - 60 Years

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind